Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects
NCT05711394Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2023
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of atogepant in episodic migraine (8 arms), sponsored by AbbVie Inc. Primary endpoints: Mean Monthly Migraine Days at 12 weeks and Adverse Events at 16 weeks. Started May 2023; status: recruiting.
02
Drugs
atogepant
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT05711394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05711394.